Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $42.33 Consensus Price Target from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $42.33.

A number of equities analysts have weighed in on the company. HC Wainwright reduced their price objective on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Cantor Fitzgerald cut shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Finally, TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AlphaQuest LLC boosted its holdings in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. KBC Group NV increased its position in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics in the 4th quarter valued at $90,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $11.38 on Monday. The stock’s 50-day simple moving average is $12.00 and its 200-day simple moving average is $38.26. The firm has a market capitalization of $461.60 million, a PE ratio of -2.18 and a beta of 1.39. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Sell-side analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.